A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Study summary

The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986315 and Nivolumab

Plus 4 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV · Recurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 16, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Bristol-Myers Squibb
Interventions being studied: Drug: BMS-986315; Drug: Nivolumab; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→Recurrent or relapsed→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participants must have NSCLC with Stage IV or recurrent disease following multimodal therapy for locally advanced disease.
Study treatment must be first-line therapy for Stage IV or recurrent disease.
Participants in all parts of the study must have:
measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1. (RECIST v1.1)
an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
a life expectancy of at least 3 months at the time of first dose

Reasons someone may not be able to joinExclusion criteria

Untreated symptomatic central nervous system metastases
Participants with epidermal growth factor receptor (EGFR)/ALK receptor tyrosine kinase (ALK)/ROS proto-oncogene 1 (ROS1)/neurotrophic tyrosine receptor kinase (NTRK)/MET proto-oncogene (MET)/B-Raf proto-oncogene (BRAF)/RET proto-oncogene (RET) mutations amenable to targeted therapies
Participants with any known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results Note: Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Local Institution - 0038Glendale, California
Local Institution - 0044Clermont, Florida
Local Institution - 0040Orange City, Florida
Local Institution - 0058Boise, Idaho
Local Institution - 0049Houston, Texas
Local Institution - 0013St Leonards, New South Wales
Local Institution - 0021Tweed Heads, New South Wales
Local Institution - 0032Joondalup, Western Australia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 16, 2025. Always confirm current availability with the study team.

View original record ↗